Zobrazeno 1 - 10
of 74
pro vyhledávání: '"Andrew G. Gianoukakis"'
Autor:
Andrew G Gianoukakis, Jennifer H Choe, Daniel W Bowles, Marcia S Brose, Lori J Wirth, Taofeek Owonikoko, Svetlana Babajanyan, Francis P Worden
Publikováno v:
European Thyroid Journal, Vol 13, Iss 1, Pp 1-13 (2024)
Background: The optimal timing for initiating multi-kinase inhibitors (MKIs) in patients with radioactive iodine-refractory (RAI-R) differentiated thyroid cancer (DTC) remains unclear. Thus, we evaluated the real-world practice patterns and outcomes
Externí odkaz:
https://doaj.org/article/4362b3a229454c4c935fbc2568fe4ec8
Autor:
Matthew H. Taylor, Sophie Leboulleux, Yury Panaseykin, Bhavana Konda, Christelle de LaFouchardiere, Brett G. M. Hughes, Andrew G. Gianoukakis, Young Joo Park, Ilia Romanov, Monika K. Krzyzanowska, Diana Garbinsky, Bintu Sherif, Jie Janice Pan, Terri A. Binder, Nicholas Sauter, Ran Xie, Marcia S. Brose
Publikováno v:
Cancer Medicine, Vol 12, Iss 4, Pp 4332-4342 (2023)
Abstract Background In the phase 2 double‐blind Study 211, a starting dose of lenvatinib 18 mg/day was compared with the approved starting dose of 24 mg/day in patients with radioiodine‐refractory differentiated thyroid cancer (RR‐DTC). Predefi
Externí odkaz:
https://doaj.org/article/dc0ec1a8bab345c086c5e789e1eef9a5
Autor:
Mohamed A. Gouda, Emily Ong, Helen J. Huang, Laron W. McPhaul, Steve Yoon, Filip Janku, Andrew G. Gianoukakis
Publikováno v:
Endocrine. 76:491-494
Autor:
Matthew H. Taylor, Sophie Leboulleux, Yury Panaseykin, Bhavana Konda, Christelle de La Fouchardiere, Brett G. M. Hughes, Andrew G. Gianoukakis, Young Joo Park, Ilia Romanov, Monika K. Krzyzanowska, Diana Garbinsky, Bintu Sherif, Jie Janice Pan, Terri A. Binder, Nicholas Sauter, Ran Xie, Marcia S. Brose
Publikováno v:
Cancer medicineREFERENCES.
In the phase 2 double-blind Study 211, a starting dose of lenvatinib 18 mg/day was compared with the approved starting dose of 24 mg/day in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). Predefined criteria for noninferi
Autor:
Andrew G. Gianoukakis, Susanne Arnold, Saad Khan, Matthew Taylor, Hendrik-Tobias Arkenau, Liz Clark, Geoffrey Fisher, Vivek Subbiah
Publikováno v:
Cancer Research. 83:CT252-CT252
Background: Addressing resistance to 1st generation selective RET inhibitors (SRI) is an area of high unmet need, with a number of RET dependent and independent pathways identified1,2. The ideal profile of a next generation SRI has been proposed: bro
Publikováno v:
Thyroid
Background: The prevalence and clinical significance of de novo detection of anti-thyroglobulin antibodies (TgAbs) during the follow-up of patients with differentiated thyroid cancer (DTC) is unknown. Methods: We utilized the National Thyroid Cancer
Autor:
Mohamed A, Gouda, Emily, Ong, Helen J, Huang, Laron W, McPhaul, Steve, Yoon, Filip, Janku, Andrew G, Gianoukakis
Publikováno v:
Endocrine. 76(2)
Autor:
Ran Xie, Matthew H. Taylor, Young Joo Park, Sophie Leboulleux, Andrew G. Gianoukakis, Corina E. Dutcus, Monika K. Krzyzanowska, Bhavana Konda, Brett G.M. Hughes, Terri A. Binder, Marcia S. Brose, Ilia Romanov, Christelle De La Fouchardiere, Yury Panaseykin
Publikováno v:
The Journal of clinical endocrinology and metabolism. 107(3)
Background Lenvatinib is a multikinase inhibitor approved to treat radioiodine-refractory differentiated thyroid cancer (RR-DTC) at a starting dose of 24 mg/day. This study explored, in a double-blinded fashion, whether a starting dose of 18 mg/day w
Autor:
Janet B. McGill, Andrew G. Gianoukakis, Elias S. Siraj, Paris Roach, Christopher R. McCartney, Mark W. True, Geetha Gopalakrishnan
Publikováno v:
J Grad Med Educ
Autor:
Corina E. Dutcus, Andrew G. Gianoukakis, Marcia S. Brose, Lori J. Wirth, Katsuki Fujino, Hideaki Miyagishi, Takuya Suzuki, Makoto Tahara
Publikováno v:
Opuholi Golovy i Šei, Vol 9, Iss 1, Pp 38-50 (2019)
Введение. В исследовании III фазы по изучению эффективности ленватиниба (E7080) в лечении дифференцированного рака щитовидной железы (Studyof (E